Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B., et al. (2006) Hypoxia-Inducible Factor Determines Sensitivity to Inhibitors of mTOR in Kidney Cancer. Nature Medicine, 12, 122-127.
http://dx.doi.org/10.1038/nm1337

has been cited by the following article:

• TITLE: The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies

  AUTHORS: Niraj Shenoy, Makardhwaj Shrivastava, Vineeth Sukrithan, Dimitra Papaspyridi, Karine Darbinyan

  KEYWORDS: Hypoxia Inducible Factor (HIF), Cancer Therapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.6, June 17, 2015

  ABSTRACT: The Hypoxia Inducible factor (HIF) pathway is known to be constitutionally active in various cancers and is the dominant pathway in some cancers such as VHL mutant clear cell Renal cell carcinoma. HIF-1α and HIF-2α overexpression is known to be important for tumor cell proliferation, maintenance of stemness and angiogenesis. There has been growing interest in therapeutic strategies targeting the HIF pathway over the last decade. We review in this section the role of hypoxia inducible factor pathway in carcinogenesis, its crosstalk with other pathways and potential cancer therapeutic strategies targeting the HIF pathway, its upstream regulators and downstream signaling.